CA3153877C - Curcuminoid composition and its therapeutic potential in managing lung fibrosis - Google Patents

Curcuminoid composition and its therapeutic potential in managing lung fibrosis Download PDF

Info

Publication number
CA3153877C
CA3153877C CA3153877A CA3153877A CA3153877C CA 3153877 C CA3153877 C CA 3153877C CA 3153877 A CA3153877 A CA 3153877A CA 3153877 A CA3153877 A CA 3153877A CA 3153877 C CA3153877 C CA 3153877C
Authority
CA
Canada
Prior art keywords
composition
demethoxycurcumin
hexahydrocurcuminoids
octahydrocurcuminoids
tetrahydrocurcuminoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3153877A
Other languages
English (en)
French (fr)
Other versions
CA3153877A1 (en
Inventor
Muhammed Majeed
Kalyanam Nagabhushanam
Lakshmi MUNDKUR
Rajendran Ramanujam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3153877A1 publication Critical patent/CA3153877A1/en
Application granted granted Critical
Publication of CA3153877C publication Critical patent/CA3153877C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3153877A 2019-10-15 2020-10-15 Curcuminoid composition and its therapeutic potential in managing lung fibrosis Active CA3153877C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962915068P 2019-10-15 2019-10-15
US62/915,068 2019-10-15
PCT/US2020/055802 WO2021076771A1 (en) 2019-10-15 2020-10-15 Curcuminoid composition and its therapeutic potential in managing lung fibrosis

Publications (2)

Publication Number Publication Date
CA3153877A1 CA3153877A1 (en) 2021-04-22
CA3153877C true CA3153877C (en) 2024-04-02

Family

ID=75382361

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3153877A Active CA3153877C (en) 2019-10-15 2020-10-15 Curcuminoid composition and its therapeutic potential in managing lung fibrosis
CA3153879A Pending CA3153879A1 (en) 2019-10-15 2020-10-15 Curcuminoid composition for therapeutic management of metabolic syndrome

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3153879A Pending CA3153879A1 (en) 2019-10-15 2020-10-15 Curcuminoid composition for therapeutic management of metabolic syndrome

Country Status (6)

Country Link
US (2) US11707438B2 (https=)
EP (2) EP4045478B1 (https=)
JP (2) JP2022553173A (https=)
CN (2) CN114746102A (https=)
CA (2) CA3153877C (https=)
WO (2) WO2021076766A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230255969A1 (en) * 2020-07-23 2023-08-17 National University Of Singapore Targeting immune pathologies induced by highly pathogenic coronaviruses
JP2023554640A (ja) * 2020-12-17 2023-12-28 サミ－サビンサ グループ リミテッド 慢性炎症状態において終末糖化産物受容体（ｒａｇｅ）を標的とするための組成物
WO2022203674A1 (en) * 2021-03-25 2022-09-29 Majeed, Muhammed Compositions and methods for managing nephropathy
BR112023022756A2 (pt) * 2021-04-30 2024-01-02 Sami Sabinsa Group Ltd Composições para gerenciamento de síndrome de ovário policístico

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0249747A (ja) 1988-08-12 1990-02-20 Kobe Steel Ltd 抗酸化剤
US6653327B2 (en) * 1999-04-09 2003-11-25 Sabinsa Corporation Cross-regulin composition of tumeric-derived tetrahydrocurcuminoids for skin lightening and protection against UVB rays
JP2003002827A (ja) * 2001-06-20 2003-01-08 Kyowa Hakko Kogyo Co Ltd 血中中性脂肪の増加の予防又は改善剤
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
US20060263309A1 (en) * 2005-05-17 2006-11-23 Bissett Donald L Regulation of mammalian keratinous tissue using personal care compositions comprising tetrahydrocurcumin
US20080031980A1 (en) * 2006-08-02 2008-02-07 Al Rodriguez Curcumin-containing composition, methods of making, and methods of using
US20080058426A1 (en) * 2006-08-29 2008-03-06 Muhammed Majeed Composition and method for treating psoriasis
CN101255119B (zh) * 2008-01-07 2014-05-21 沈阳药科大学 四氢姜黄素衍生物及盐类
JP2012521412A (ja) * 2009-03-23 2012-09-13 ライラ ファーマシューティカルズ ピーブイティ．エルティディ． 鼻のアレルギー疾患において適用するためのクルクミノイドおよびその代謝物
CN101732292B (zh) * 2010-01-25 2012-05-16 四川省中医药科学院 四氢姜黄素的用途
CN102526004A (zh) * 2010-01-25 2012-07-04 四川省中医药科学院 四氢姜黄素的新用途
WO2011124573A1 (en) * 2010-04-09 2011-10-13 Unilever Plc Oral care compositions
CN102078312A (zh) * 2010-12-24 2011-06-01 中国药科大学 一种姜黄素类化合物干粉吸入剂及其制备方法和用途
US9170257B2 (en) * 2012-06-14 2015-10-27 Signpath Pharma Inc. Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin
US20150283093A1 (en) * 2014-04-07 2015-10-08 Muhammed Majeed Nanoencapsulation of curcuminoid metabolites - process, composition and applications thereof
US9642886B2 (en) * 2014-08-25 2017-05-09 Srm University Plant based formulation for the prevention and management of metabolic syndrome by its adiponectin enhancing property
DK3233068T3 (da) * 2014-12-15 2021-09-13 Aurea Biolabs Private Ltd Fremgangsmåde til fremstilling af biotilgængelig hvid curcumin - en unik blanding af hydrogenerede curcuminoider
KR102876481B1 (ko) * 2017-03-17 2025-10-27 케랄라 아유르베다 리미티드 (인디아) 약초 조성물
CN108771664B (zh) * 2018-06-05 2020-09-08 中山大学 四氢姜黄素在改善过敏性哮喘的应用
CN109833457A (zh) * 2019-02-28 2019-06-04 孟凤仙 虎杖及姜黄及其活性物在治疗间质性肺病中的应用
CN109674742A (zh) * 2019-03-07 2019-04-26 康赋葆(深圳)生物医药科技有限公司 一种姜黄素类亲水凝胶骨架缓释组合物、制备方法及其在抗癌领域的应用

Also Published As

Publication number Publication date
EP4045478B1 (en) 2026-01-28
US11491119B2 (en) 2022-11-08
CN114746102A (zh) 2022-07-12
US20210106544A1 (en) 2021-04-15
EP4045071A1 (en) 2022-08-24
EP4045478A4 (en) 2024-01-10
CA3153879A1 (en) 2021-04-22
CA3153877A1 (en) 2021-04-22
EP4045071A4 (en) 2023-11-29
CN114728876A (zh) 2022-07-08
EP4045071B1 (en) 2026-02-25
EP4045478A1 (en) 2022-08-24
WO2021076766A1 (en) 2021-04-22
WO2021076771A1 (en) 2021-04-22
US20210106543A1 (en) 2021-04-15
JP2022551967A (ja) 2022-12-14
US11707438B2 (en) 2023-07-25
JP2022553173A (ja) 2022-12-22

Similar Documents

Publication Publication Date Title
CA3153877C (en) Curcuminoid composition and its therapeutic potential in managing lung fibrosis
Ansari et al. Sinapic acid mitigates gentamicin-induced nephrotoxicity and associated oxidative/nitrosative stress, apoptosis, and inflammation in rats
Yaman et al. Protective effects of Nigella sativa against gentamicin-induced nephrotoxicity in rats
Yazdanparast et al. Experimental diabetes treated with Achillea santolina: effect on pancreatic oxidative parameters
JP5443754B2 (ja) バクチオール組成物およびその調製方法
Lai et al. Attenuation of cyclosporine A induced nephrotoxicity by schisandrin B through suppression of oxidative stress, apoptosis and autophagy
JP6159084B2 (ja) 酒さまたは赤面に関連する皮膚疾患を治療するための、ベルベリンまたはその類似体を含有する組成物
Wirotesangthong et al. Inhibitory effects of Piper betle on production of allergic mediators by bone marrow-derived mast cells and lung epithelial cells
US9265808B2 (en) Compositions for alleviating inflammation and oxidative stress in a mammal
Huang et al. Geraniin protects bone marrow‑derived mesenchymal stem cells against hydrogen peroxide‑induced cellular oxidative stress in vitro
Rashid et al. Abrogation of 5-flourouracil induced renal toxicity by bee propolis via targeting oxidative stress and inflammation in Wistar rats
Fuentes et al. Protection against indomethacin-induced loss of intestinal epithelial barrier function by a quercetin oxidation metabolite present in onion peel: In vitro and in vivo studies
US20160045561A1 (en) Antioxidatively Active Composition and the Use Thereof
Chen et al. Dexmedetomidine ameliorates renal ischemia reperfusion-mediated activation of the NLRP3 inflammasome in alveolar macrophages
JP2011012052A (ja) 海藻の抽出物を有効成分として含有する抗炎症組成物
Azis et al. Blood pressure lowering effect of Ficus deltoidea var kunstleri in spontaneously hypertensive rats: possible involvement of renin–angiotensin–aldosterone system, endothelial function and anti-oxidant system
Singh et al. Evaluation of nephroprotective activity of Mentha Arvensis l. in cisplatin induced nephrotoxicity
Jain et al. Comparison of antifungal effect of Aloevera gel and Triphala: An: in vitro: study
Farias et al. Uncaria tomentosa stimulates the proliferation of myeloid progenitor cells
KR20170093166A (ko) 감소된 양의 리코펜을 갖는 생물학적-활성 토마토 조성물
WO2019112990A1 (en) Compositions for microbial anti-adhesion
Ansari A comparative anti-inflammatory and antioxidative potent of Nigella sativa seeds extract and its oil
US12053500B2 (en) Compositions for management of acute nephrotoxicity
JP2020524662A (ja) バチルス・コアグランスｍｔｃｃ ５８５６から単離された細胞外代謝物のアンチエイジング能
Ghosh et al. Tinospora cordifolia in the treatment of chronic and aggressive periodontitis patients with and without dental fluorosis: A clinical, microbiological, and biochemical study

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220406

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: OFFER OF REMISSION

Effective date: 20250619

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REMISSION NOT REFUSED

Effective date: 20250619

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250619

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REMITTANCE APPROVED

Effective date: 20250621

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251010

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251010